Publications by authors named "Simon Chowdhury"

Claim this Profile
A
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, Randy Vince, Umang Swami, Simon Chowdhury

Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.
Soumyajit Roy, Yilun Sun, Maha Hussain, Kim N Chi, Karim Fizazi, Simon Chowdhury

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Silke Gillessen, Laura Murphy, Nicholas D James, Ashwin Sachdeva, Omar El-Taji, Simon Chowdhury

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.
Soumyajit Roy, Zeynep Irem Ozay, Avirup Guha, Yilun Sun, Kim N Chi, Simon Chowdhury

JAMA Netw Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Ciara Conduit, Andrisha-Jade Inderjeeth, Raymond Allen, Andrew J Martin, Wendy Parulekar, Simon Chowdhury

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.
Maria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, Suparna Thakali, Anna Wingate, Simon Chowdhury

Eur Urol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
Ding-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, Hiroyoshi Suzuki, Suneel Mundle, Simon Chowdhury

Int J Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, Hirotsugu Uemura, Alvaro Juarez Soto, Simon Chowdhury

BJU Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial.
Soumyajit Roy, Yilun Sun, Kim N Chi, Michael Ong, Shawn Malone, Simon Chowdhury

J Urol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.
Soumyajit Roy, Fred Saad, Yilun Sun, Shawn Malone, Daniel E Spratt, Simon Chowdhury

Eur J Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
Axel S Merseburger, Simon Chowdhury, Amit Bahl

Eur Urol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.
Soumyajit Roy, Shawn Malone, Kevin Wing, Simon Chowdhury, Amar U Kishan

JAMA Netw Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eric J Small, Kim N Chi, Simon Chowdhury, Katherine B Bevans, Amitabha Bhaumik

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
Gavin Marx, Simon Chowdhury, Laurence Krieger, Elizabeth Hovey, Jeremy Shapiro

Asia Pac J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
Soumyajit Roy, Fred Saad, Shawn Malone, Neeraj Agarwal, Osama Mohamad, Simon Chowdhury

Eur Urol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Simon Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung H Chung, Robert W Given

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
John Shen, Simon Chowdhury, Neeraj Agarwal, Lawrence I Karsh, Stéphane Oudard

Br J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Byung Ha Chung, Jian Huang, Hiroji Uemura, Young Deuk Choi, Zhang-Qun Ye, Simon Chowdhury

Asian J Androl· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, Laurence I Karsh, Simon Chowdhury

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Alan H Bryce, Jeremy Shapiro, Simon Chowdhury

Eur Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews.
Darren Leaning, Gagandeep Kaur, Alicia K Morgans, Ray Ghouse, Osvaldo Mirante, Simon Chowdhury

Front Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Simon Chowdhury

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Simon Chowdhury

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Leanna Cheung, Simon Chowdhury

Lancet Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis